This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01401244
First received: July 20, 2011
Last updated: February 23, 2017
Last verified: February 2017
  Purpose
This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.

Condition Intervention Phase
Genetic Disorder Prader-Willi Syndrome Growth Disorder Idiopathic Short Stature Healthy Drug: somatropin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Trial to Examine the Bioequivalence of Norditropin® Versus Genotropin® in Healthy Adult Volunteers

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Area under the serum hGH (human growth hormone) concentration-time curve [ Time Frame: from 0 to the time of the last quantifiable concentration over a 24-hour sampling period ]
  • Maximum observed serum hGH concentration [ Time Frame: over a 24-hour sampling period ]

Secondary Outcome Measures:
  • Area under the effect (IGF-I) curve [ Time Frame: from time 0 to the time of the last concentration (AUEC0-t) over a 96-hour sampling period ]
  • Maximum IGF-I effect (Emax) [ Time Frame: over a 96-hour sampling period ]
  • The frequency of adverse events (AE) [ Time Frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product) ]
  • The frequency of injection site reaction [ Time Frame: from the time of injection of the trial product (day 1 and 13, respectively) to follow-up during the two dosing periods (day 5 and 17, respectively) ]
  • Abnormal hematology laboratory parameters [ Time Frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product) ]
  • Abnormal biochemistry laboratory parameters [ Time Frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product) ]
  • Abnormal findings in physical examinations [ Time Frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product) ]
  • Vital signs [ Time Frame: from screening (3-14 days before first dose of trial product) to follow-up period (day 17 after first dose of trial product) ]

Enrollment: 30
Actual Study Start Date: July 14, 2011
Study Completion Date: September 27, 2011
Primary Completion Date: September 27, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Norditropin® Drug: somatropin
A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
Active Comparator: Genotropin® Drug: somatropin
A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index (BMI) 18.0-27.0 kg/m^2 (both inclusive)
  • Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator (trial physician)

Exclusion Criteria:

  • The receipt of any investigational medicinal product within 1 month prior to this trial
  • Current or previous treatment with growth hormone or IGF-I (insulin-like growth factor-I)
  • Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) for the duration of the trial
  • Known presence or history of malignancy
  • Diabetes mellitus
  • Use of pharmacologic doses of glucocorticoids
  • Use of anabolic steroids
  • History of drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01401244

Locations
United States, Indiana
Novo Nordisk Investigational Site
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01401244     History of Changes
Other Study ID Numbers: GH-3939
U1111-1121-3640 ( Other Identifier: WHO )
Study First Received: July 20, 2011
Last Updated: February 23, 2017

Additional relevant MeSH terms:
Disease
Prader-Willi Syndrome
Dwarfism
Growth Disorders
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Obesity
Overnutrition
Nutrition Disorders
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on June 23, 2017